• Publications
  • Influence
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Low-dose olanzapine (5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating agitation/aggression and psychosis in this population of patients with AD. Expand
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated. Expand
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
The most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness. Expand
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
The olanzapine/fluoxetine combination did not differ significantly from the other therapies at endpoint, although it demonstrated a more rapid response that was sustained until the end of treatment. Expand
Olanzapine versus Placebo and Haloperidol
Olanzapine is a potential new “atypical” antipsychotic agent. The double-blind acute phase of this study compared three dosage ranges of olanzapine (5 ± 2.5 mg/day [Olz-L], 10 ± 2.5 mg/day [Olz-M],Expand
Olanzapine versus placebo in the treatment of acute mania
The results from this study suggest that compared with placebo, olanzapine has superior efficacy for the symptoms of acute mania. Expand
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Olanzapine appears to be not only safe and effective, but a promising atypical antipsychotic candidate. Expand
Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial
A receiver operating characteristic (ROC) curve analysis of 12-hour olanzapine concentrations and treatment response from the North American Double-Blind Olanzapine Trial found a 12- hour olanZapine plasma concentration of >23.2 ng/mL was a predictor of therapeutic response in acutely ill patients with schizophrenia. Expand
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
Patients with TRD (defined as treatment failure on 2 antidepressants) taking olanzapine/fluoxetine combination demonstrated significantly greater improvement in depressive symptoms than patients taking oanzapine or fluxetine in 1 of 2 studies and in the pooled analysis. Expand
A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression
The OFC had a safety profile comparable to its component monotherapies, showed a rapid onset of antidepressant effect, and was effective in this TRD sample. Expand